Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
| Autor: | Shoji Takakura, Yuka Hayashizaki-Someya, Kumi Koide, Shunji Yamazaki, Toshiyuki Takasu, Hikaru Mitori, Eiji Kurosaki |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Thiophenes chemistry.chemical_compound Glucosides Non-alcoholic Fatty Liver Disease Fibrosis Internal medicine Nonalcoholic fatty liver disease medicine Animals Hypoglycemic Agents Amino Acids Sodium-Glucose Transporter 2 Inhibitors Triglycerides Food Formulated Inflammation Pharmacology Pioglitazone business.industry medicine.disease Choline Deficiency Rats Renal glucose reabsorption Hydroxyproline Endocrinology Ipragliflozin chemistry Thiazolidinediones Steatosis SGLT2 Inhibitor Hepatic fibrosis business medicine.drug |
| Zdroj: | European Journal of Pharmacology. 754:19-24 |
| ISSN: | 0014-2999 |
| Popis: | Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect. As nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is closely linked to metabolic diseases such as obesity and diabetes, we investigated the effect of ipragliflozin on NAFLD in rats fed a choline-deficient l-amino acid-defined (CDAA) diet. Five weeks after starting the CDAA diet, rats exhibited hepatic triglyceride (TG) accumulation, fibrosis, and mild inflammation. Repeated oral administration of ipragliflozin (3mg/g, once daily for 5 weeks) prevented both hepatic TG accumulation (188 vs.290 mg/g tissue vehicle-treated group; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect